GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
World game at war: why some European nations have threatened a World Cup boycott 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
MINNEAPOLIS, May 02, 2018 -- Inspire Medical Systems, Inc. (NYSE:INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the pricing of its initial public offering of 6,750,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Inspire. In addition, Inspire has granted the underwriters a 30-day option to purchase up to 1,012,500 additional shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on May 3, 2018 under the ticker symbol “INSP.” The offering is expected to close on May 7, 2018, subject to customary closing conditions.
BofA Merrill Lynch and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. Guggenheim Securities, Stifel and Wells Fargo Securities are acting as co-managers for the offering.
A registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: [email protected]; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Inspire Investor and Media Contact
Bob Yedid
LifeSci Advisors
[email protected]
646-597-6989
